



Division of Public Health Services

Office of the Assistant Director

Public Health Preparedness Services

Bureau of Emergency Medical Services and Trauma System

150 N. 18th Avenue, Suite 540
Phoenix, Arizona 85007
(602) 364-3150 / 1-800-200-8523
(602) 364-3568 FAX

DOUGLAS A. DUCEY, GOVERNOR
CARA M. CHRIST, MD, DIRECTOR

PROTOCOLS, MEDICATIONS & DEVICES (PMD)

STANDING COMMITTEE

Date: November 19, 2015 - **Time:** 12:00 PM

Location: 150 N. 18th Ave., Conference Rooms 215 A&B

Conference Call: 1-877-820-7831 - **Code:** 450908#

iLinc URL: <https://azdhsems.ilinc.com/join/xcphsxt>

You must register prior to the meeting to join the web conference session.

AGENDA

- I. Call to Order – Toni Gross, MD, Chair
- II. Roll Call – Jennifer Herbert (13 Members, 7 required for quorum)
- III. Chairman’s Report – Toni Gross, MD
 - a. Attendance report (Attachment III.a.)
 - b. 2016 Meeting schedule (Attachment III.b.)
 - c. Welcome new members: Peter Rhee, MD, and Franco Castro-Marin, MD
 - d. Vacancies: EMS Council Liaison & AEMS Representative
 - e. 2015 AHA Guidelines Update for CPR and ECC available: *Circulation* Nov. 3, 2015, Volume 132, Issue 18, suppl 2. http://circ.ahajournals.org/content/132/18_suppl_2.toc
- IV. Bureau Report – Noreen Adlin
 - a. Rules update
- V. Discussion and Action Items
 - a. Discuss, amend, approve, PMD minutes of July 16, 2015 (Attachment V.a.).
 - b. Discuss and approve the addition of Hydroxyethyl Starch with Lactated Ringers as an Optional Agent for Paramedics only to the Drug Box, Table 5.2 – Garth Gemar, MD and Kari Jerge, MD (Attachment V.b.)
 - c. Discuss, amend, approve the Hydroxyethyl Starch with Lactated Ringers Drug Profile – Garth Gemar, MD and Kari Jerge, MD (Attachment V.c.)
 - d. Discuss and approve adding TXA to Table 5.2 (Drug Box) as an Optional Agent – Garth Gemar, MD and Kari Jerge, MD (Attachment V.b.)

Persons with disabilities may request reasonable accommodations such as a sign language interpreter, by Angie McNamara, Program Project Specialist II, 602-364-3156; State TDD Number 1-800-367-8939; or Voice Relay Number 711. Request should be made as early as possible to allow time to arrange accommodations.

“Health and Wellness for all Arizonans”

- e. Discuss, amend, approve the TXA Drug Profile – Garth Gemar, MD and Kari Jerge, MD (Attachment V.e.)
- f. Discuss, amend, approve adding Lidocaine for IO Pain Management as an optional agent to Table 5.2 – Tracy Meiner (Attachments V.b. & V.f.)
- g. Discuss, amend, approve revising TTTGs – Toni Gross, MD
 - i. Adult & Pediatric Shock (Attachment V.g.i.)
 - ii. Adult & Pediatric Seizures (Attachment V.g.ii.)
 - iii. Post-Resuscitation of Circulation (ROSC) Care and Transport to Cardiac Receiving Center (Attachment V.g.iii.)
 - iv. Adult & Pediatric Difficulty Breathing – Bronchospasm (Attachment V.g.iv.)

VI. Agenda Items for Next Meeting

- VII. Call to the Public: A public body may make an open call to the public during a public meeting, subject to reasonable time, place and manner restrictions, to allow individuals to address the public body on any issue within the jurisdiction of the public body. At the conclusion of an open call to the public, individual members of the public body may respond to criticism made by those who have addressed the public body, may ask staff to review a matter, or may ask that a matter be put on a future agenda. Members of the public body shall not discuss or take legal action on matters raised during an open call to the public unless the matters are properly noticed for discussion and legal action. A.R.S. § 38-431.01 (G).

Members of the public body may present a brief summary of current events. Members of the public body shall not propose, discuss, deliberate, or take legal action on matters raised during a summary of current events unless the matters are properly noticed for discussion and legal action.

VIII. Summary of Current Events

- a. AFDA – Laughlin, Nevada – January 12- 14, 2016 - <http://www.azfiredistricts.org/conferences/>
- b. Arizona Trauma Association Presents: Game Day Sunday, - February 7, 2016 <http://www.aztracc.org/tackletrauma5k/>
- c. Trauma Conference International – July 14 – 15, 2016 – Hotel Coronado, Coronado, CA <http://traumacon.org/>

- IX. Next Meetings: March 17, 2016 @ 12:00 PM in Rooms 215A&B, 150 N. 18th Ave.
 July 21, 2016 @ 12:00 PM in Rooms 215A&B, 150 N. 18th Ave.
 November 17, 2016 @ 12:00 PM in Rooms 215A&B, 150 N. 18th Ave.

X. Adjournment

Persons with disabilities may request reasonable accommodations such as a sign language interpreter, by Angie McNamara, Program Project Specialist II, 602-364-3156; State TDD Number 1-800-367-8939; or Voice Relay Number 711. Request should be made as early as possible to allow time to arrange accommodations.

“Health and Wellness for all Arizonans”

Committee Attendance Report

Protocols, Medications & Devices Committee

Protocols, Medications & Devices Committee

		Present	Tele	Absent
Bruce Toliver	AEMS Representative			
	2/2/2012	<input type="checkbox"/>	<input checked="" type="checkbox"/>	<input type="checkbox"/>
	5/24/2012	<input type="checkbox"/>	<input checked="" type="checkbox"/>	<input type="checkbox"/>
	11/15/2012	<input type="checkbox"/>	<input checked="" type="checkbox"/>	<input type="checkbox"/>
	3/21/2013	<input type="checkbox"/>	<input checked="" type="checkbox"/>	<input type="checkbox"/>
	7/18/2013	<input type="checkbox"/>	<input type="checkbox"/>	<input checked="" type="checkbox"/>
	11/21/2013	<input type="checkbox"/>	<input type="checkbox"/>	<input checked="" type="checkbox"/>
	3/20/2014	<input type="checkbox"/>	<input checked="" type="checkbox"/>	<input type="checkbox"/>
	7/17/2014	<input type="checkbox"/>	<input type="checkbox"/>	<input checked="" type="checkbox"/>
	11/20/2014	<input type="checkbox"/>	<input type="checkbox"/>	<input checked="" type="checkbox"/>
	3/19/2015	<input type="checkbox"/>	<input checked="" type="checkbox"/>	<input type="checkbox"/>
7/16/2015	<input type="checkbox"/>	<input checked="" type="checkbox"/>	<input type="checkbox"/>	
Charlie Smith	EMS Council Liaison			
	2/2/2012	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
	5/24/2012	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
	11/15/2012	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
	3/21/2013	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
	7/18/2013	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
	11/21/2013	<input type="checkbox"/>	<input checked="" type="checkbox"/>	<input type="checkbox"/>
	3/20/2014	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
	7/17/2014	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
	11/20/2014	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
	3/19/2015	<input type="checkbox"/>	<input type="checkbox"/>	<input checked="" type="checkbox"/>
7/16/2015	<input type="checkbox"/>	<input type="checkbox"/>	<input checked="" type="checkbox"/>	
Gail Bradley	AEMS Representative			
	3/20/2014	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
	7/17/2014	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
	11/20/2014	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
	3/19/2015	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
	7/16/2015	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
Garth Gemar	AEMS Representative			
	2/2/2012	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
	5/24/2012	<input type="checkbox"/>	<input checked="" type="checkbox"/>	<input type="checkbox"/>
	11/15/2012	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
	3/21/2013	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
	7/18/2013	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
	11/21/2013	<input type="checkbox"/>	<input checked="" type="checkbox"/>	<input type="checkbox"/>
	3/20/2014	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
	7/17/2014	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
	11/20/2014	<input type="checkbox"/>	<input type="checkbox"/>	<input checked="" type="checkbox"/>
	3/19/2015	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
7/16/2015	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	
Heather Miller	WACEMS Representative			
	7/16/2015	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
Jason Johnson	NAEMS Representative			
	11/15/2012	<input type="checkbox"/>	<input checked="" type="checkbox"/>	<input type="checkbox"/>
	3/21/2013	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>

		Present	Tele	Absent	
Jason Johnson	NAEMS Representative				
	7/18/2013	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	
	11/21/2013	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	
	3/20/2014	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	
	7/17/2014	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	
	11/20/2014	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	
	3/19/2015	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	
	7/16/2015	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	
	Josh Gaither	SAEMS Representative			
		11/21/2013	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
		3/20/2014	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
7/17/2014		<input type="checkbox"/>	<input checked="" type="checkbox"/>	<input type="checkbox"/>	
11/20/2014		<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	
3/19/2015		<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	
7/16/2015	<input type="checkbox"/>	<input checked="" type="checkbox"/>	<input type="checkbox"/>		
Michael Pflieger	AEMS Representative (STAB Liaison)				
	2/2/2012	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	
	5/24/2012	<input type="checkbox"/>	<input type="checkbox"/>	<input checked="" type="checkbox"/>	
	11/15/2012	<input type="checkbox"/>	<input type="checkbox"/>	<input checked="" type="checkbox"/>	
	3/21/2013	<input type="checkbox"/>	<input checked="" type="checkbox"/>	<input type="checkbox"/>	
	7/18/2013	<input type="checkbox"/>	<input checked="" type="checkbox"/>	<input type="checkbox"/>	
	11/21/2013	<input type="checkbox"/>	<input type="checkbox"/>	<input checked="" type="checkbox"/>	
	3/20/2014	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	
	7/17/2014	<input type="checkbox"/>	<input checked="" type="checkbox"/>	<input type="checkbox"/>	
	11/20/2014	<input type="checkbox"/>	<input checked="" type="checkbox"/>	<input type="checkbox"/>	
	3/19/2015	<input type="checkbox"/>	<input checked="" type="checkbox"/>	<input type="checkbox"/>	
7/16/2015	<input type="checkbox"/>	<input type="checkbox"/>	<input checked="" type="checkbox"/>		
Neil Gago	SAEMS Representative				
	11/20/2014	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	
	3/19/2015	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	
	7/16/2015	<input type="checkbox"/>	<input checked="" type="checkbox"/>	<input type="checkbox"/>	
Robert Jarvis	AEMS Representative				
	2/2/2012	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	
	5/24/2012	<input type="checkbox"/>	<input checked="" type="checkbox"/>	<input type="checkbox"/>	
	11/15/2012	<input type="checkbox"/>	<input type="checkbox"/>	<input checked="" type="checkbox"/>	
	3/21/2013	<input type="checkbox"/>	<input type="checkbox"/>	<input checked="" type="checkbox"/>	
	7/18/2013	<input type="checkbox"/>	<input checked="" type="checkbox"/>	<input type="checkbox"/>	
	11/21/2013	<input type="checkbox"/>	<input checked="" type="checkbox"/>	<input type="checkbox"/>	
	3/20/2014	<input type="checkbox"/>	<input type="checkbox"/>	<input checked="" type="checkbox"/>	
	7/17/2014	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	
	11/20/2014	<input type="checkbox"/>	<input type="checkbox"/>	<input checked="" type="checkbox"/>	
	3/19/2015	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	
7/16/2015	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>		
Terence Mason	Vice Chair/AEMS Representative				
	2/2/2012	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	
	5/24/2012	<input type="checkbox"/>	<input checked="" type="checkbox"/>	<input type="checkbox"/>	
	11/15/2012	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	

Protocols, Medications & Devices Committee

Present Tele Absent

		Present	Tele	Absent
Terence Mason	Vice Chair/AEMS Representative			
	3/21/2013	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
	7/18/2013	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
	11/21/2013	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
	3/20/2014	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
	7/17/2014	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
	11/20/2014	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
	3/19/2015	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
	7/16/2015	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
Toni Gross	Chair/AEMS Representative (MDC Liaison)			
	5/24/2012	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
	11/15/2012	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
	3/21/2013	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
	7/18/2013	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
	11/21/2013	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
	3/20/2014	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
	7/17/2014	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
	11/20/2014	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
	3/19/2015	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
	7/16/2015	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>

**Bureau of Emergency Medical Services and Trauma System
2016 Statutory/Standing Committee Meetings**

Date	Time	Meeting	Conference Room
January 21, 2016	9:00 a.m.	State Trauma Advisory Board	215A & 215B – 2nd Floor 150 Bldg
January 21, 2016	10:30 a.m.	Emergency Medical Services	215A & 215B – 2nd Floor 150 Bldg
January 21, 2016	12:00 p.m.	Medical Direction Commission	215A & 215B – 2nd Floor 150 Bldg
March 17, 2016	9:00 a.m.	Trauma and EMS Performance Improvement (TEPI)	215A & 215B – 2nd Floor 150 Bldg
March 17, 2016	10:30 a.m.	Education Committee	215A & 215B – 2nd Floor 150 Bldg
March 17, 2016	12:00 p.m.	Protocols, Medications and Devices Committee	215A & 215B – 2nd Floor 150 Bldg
May 19, 2016	9:00 a.m.	State Trauma Advisory Board	215A & 215B – 2nd Floor 150 Bldg
May 19, 2016	10:30 a.m.	Emergency Medical Services Council	215A & 215B – 2nd Floor 150 Bldg
May 19, 2016	12:00 p.m.	Medical Direction Commission	215A & 215B – 2nd Floor 150 Bldg
July 21, 2016	9:00 a.m.	Trauma and EMS Performance Improvement (TEPI)	215A & 215B – 2nd Floor 150 Bldg
July 21, 2016	10:30 a.m.	Education Committee	215A & 215B – 2nd Floor 150 Bldg
July 21, 2016	12:00 p.m.	Protocols, Medications and Devices Committee	215A & 215B – 2nd Floor 150 Bldg
September 15, 2016	9:00 a.m.	State Trauma Advisory Board	215A & 215B – 2nd Floor 150 Bldg
September 15, 2016	10:30 a.m.	Emergency Medical Services Council	215A & 215B – 2nd Floor 150 Bldg
September 15, 2016	12:00 p.m.	Medical Direction Commission	215A & 215B – 2nd Floor 150 Bldg
November 17, 2016	9:00 a.m.	Trauma and EMS Performance Improvement (TEPI)	215A & 215B – 2nd Floor 150 Bldg
November 17, 2016	10:30 a.m.	Education Committee	215A & 215B – 2nd Floor 150 Bldg
November 17, 2016	12:00 p.m.	Protocols, Medications and Devices Committee	215A & 215B – 2nd Floor 150 Bldg

DISCLAIMER: “Meeting schedule subject to change upon the request of the Governor’s Office or the Office of the Director. Should this occur, the Bureau will make all reasonable efforts to contact the affected members as soon as feasible.”

PROTOCOLS, MEDICATIONS & DEVICES (PMD) STANDING COMMITTEE

Date: July 16, 2015 - **Time:** 12:00 PM

Location: 150 N. 18th Ave., Conference Room 540 A

DRAFT Meeting Minutes

- I. Call to Order – Toni Gross, MD, Chair. Meeting was called to order at 12:02 pm
- II. Roll Call – Toni Gross, MD, (12 Members, 7 required for quorum). A quorum was present.

Members Present

Gail Bradley, MD
Jason Johnson, MD
Josh Gaither, MD*
Robert Jarvis
Neil Gago*
Terence Mason
Toni Gross, MD

Bruce Toliver*
Sue Kern*
Garth Gemar

Members Absent

Charlie Smith
Michael Pfleger, MD

- III. Chairman’s Report – Toni Gross, MD
 - a. Attendance report. Members reviewed the attendance report and there were no comments
- IV. Bureau Report – Noreen Adlin
 - a. Rules update: HB 2489 adopted
 - b. Education Curricula for Pain Management Protocol – Toni Gross, MD
- V. Discussion and Action Items
 - a. Discuss, amend, approve, PMD minutes of March 19, 2015. Gail Bradley, MD, made the motion, seconded by Garth Gemar, MD. **Motion carries.**
 - b. Discuss and approve adding the new membership category of Trauma Surgeon to the PMD Bylaws – Toni Gross, MD. Garth Gemar, MD, made the motion to approve the changes, seconded by Robert Jarvis. **Motion carries.**
 - c. Discuss the TTTG document review – Toni Gross, MD. The algorithm format will remain the format for the TTTG. A discussion about how to best revise the TTTG ensued. Dr. Gross will assign sections to PMD volunteers for reviewing the TTTG. No motion.
 - i. Discuss, amend, approve the Pain Management TTTG – Toni Gross and Robert Jarvis
 - ii. Discuss, amend, approve the Shock TTTG – Toni Gross and Bruce Toliver
 - iii. Discuss, amend, approve the Altered Mental Status TTTG – Gail Bradley and Kim Choppi
 - iv. Discuss, amend, approve the Hyperthermia/Heat Exposure TTTG – Sue Kern and Terry Mason
 - v. Discuss, amend, approve the Altitude Illness TTTG – Jason Johnson and Brian Smith (this will not be included in the TTTG)
 - d. Discuss, amend, approve expanding the use of Ketamine in the drug profile– Garth Gemar, MD. Jason Johnson, MD, made the motion to approve the amended drug profile, seconded by Garth Gemar, MD. A discussion ensued and the drug profile was approved with friendly amendments. **Motion carries.**
 - e. Discuss and approve adding Phytanadine on Infusion Pump (IP) to Table 5.4 (Interfacility Transport) as a Paramedic skill only – Garth Gemar, MD. Garth Gemar,

MD, made the motion to approve the addition, seconded by Terry Mason. A discussion ensued and the drug addition was approved with friendly amendments. **Motion carries.**

- f. Discuss, amend, approve the Phytonadine Drug Profile – Garth Gemar, MD. Terry Mason made the motion to approve the drug profile, seconded by Robert Jarvis. A discussion ensued and the drug profile was approved with friendly amendments. **Motion carries.**
- g. Discuss medication classes and specific agents in Table 5.2 (Drug Box) – Toni Gross, MD.
- h. Discuss and approve changes to Naloxone on Table 5.1 (Scope of Practice) – Noreen Adlin. (This item was discussed after V.a.) Jason Johnson, MD, made the motion to approve the changes, seconded by Terry Mason. **Motion carries.**

VI. Agenda Items for Next Meeting

- a. Discuss and approve the addition of Hydroxyethyl Starch with Lactated Ringers as an Optional Agent for Paramedics only to the Drug Box, Table 5.2 – Garth Gemar, MD and Kari Jerge, MD
- b. Discuss, amend, approve the Hydroxyethyl Starch with Lactated Ringers Drug Profile – Garth Gemar, MD and Kari Jerge, MD
- c. Discuss adding TXA to Table 5.2 (Drug Box) as an Optional Agent – Garth Gemar, MD and Kari Jerge, MD
- d. Discuss the TXA Drug Profile – Garth Gemar, MD and Kari Jerge, MD
- e. Discuss and approve developing drug profiles for specific drug categories for transport agents listed on Table 5.4

VII. Call to the Public: David Harden, JD, announced that the Pain Management online training course is up and running and performed a demo.

VIII. Summary of Current Events

- a. July 30-31, 2015: SW Regional Trauma Conference. J.W. Marriott Starr Pass Resort and Spa, Tucson
- b. November 2-4, 2015: National Pediatric Disaster Conference. Camelback Inn Resort and Spa, Scottsdale
- c. November 6-7, 2015: Pediatric Trauma Society Meeting. OMNI Resort & Spa Montelucia, Scottsdale
- d. November 12-13, 2015: Southwest Trauma and Acute care symposium (STACS). Talking Stick Resort, Scottsdale

IX. Next Meeting: November 19, 2015, 12:00 PM at 150 N. 18th Avenue, Rooms 215A & 215B

X. Adjournment: 1:54 PM

Approved by PMD

Date:

VISITORS PLEASE SIGN IN

PMD Committee - July 16, 2015 @ 12:00 pm

Name (PLEASE PRINT)		Organization & Position
1	RONALD MALTWERZ	FAC
2	Rebecca Haro	SCWED
3	CHRIS Thompson	YRMC
4	Sharon Hellingpounder	PCC
5	Tracy Irwin	BDWMC
6	M. Gross	CFHM
7	Laurie Wood	BTMC
8	Mark Venturi	NAEMJ
9		
10		
11		
12		
13		
14		
15		
16		
17		

Table 5.2. Eligibility for Authorization to Administer, Monitor, and Assist in Patient Self-administration of Agents by EMCT Classification; Administration Requirements; and Minimum Supply Requirements for Agents

KEY:

A = Authorized to administer the agent

SVN = Agent shall be administered by small volume nebulizer

MDI = Agent shall be administered by metered dose inhaler

* = Authorized to assist in patient self-administration

[] = Minimum supply required if an EMS provider chooses to make the optional agent available for EMCT administration

AGENT	MINIMUM SUPPLY	EMT	AEMT	EMT-I (99)	Paramedic
Adenosine	18 mg	-	-	A	A
Albuterol Sulfate SVN or MDI (sulfite free)	10 mg	A	A	A	A
Amiodarone or Lidocaine	300 mg or 3 prefilled syringes, total of 300 mg and 1 g vials or premixed infusion, total of 2 g	-	-	-	A
Aspirin	324 mg	A	A	A	A
Atropine Sulfate	3 prefilled syringes, total of 3 mg	-	-	A	A
Atropine Sulfate	Optional [8 mg multidose vial (1)]	-	-	A	A
Atropine Sulfate Auto-Injector	None	A	A	A	A
Atropine Sulfate and Pralidoxime Chloride (Combined) Auto-Injector	None	A	A	A	A
Calcium Chloride	1 g	-	-	-	A
Calcium Gluconate, 2.5% topical gel	Optional [50 g]	A	A	A	A
Charcoal, Activated (without sorbitol)	Optional [50 g]	A	A	A	A
Cyanokit	Optional [5 g]	-	-	-	A
Dexamethasone	Optional [8 mg]	-	-	A	A
Dextrose	50 g	-	A	A	A
Dextrose, 5% in H ₂ O	Optional [250 mL bag (1)]	A	A	A	A
Diazepam or Lorazepam or Midazolam	20 mg 8 mg 10 mg	-	-	A	A
Diazepam Rectal Delivery Gel	Optional [20 mg]	-	-	A	A
Diltiazem or Verapamil HCl	25 mg 10 mg	-	-	-	A
Diphenhydramine HCl	50 mg	-	-	A	A
Dopamine HCl	400 mg	-	-	-	A
Epinephrine Auto-Injector	Optional [2 adult auto-injectors 2 pediatric auto-injectors]	A	A	A	A
Epinephrine HCl, 1:1,000	2 mg	-	A	A	A

Attachment V.b.

Epinephrine HCl, 1:1,000	Optional [30 mg multidose vial (1)]	-	A	A	A
Epinephrine HCl, 1:10,000	5 mg	-	-	A	A
Etomidate	Optional [40 mg]	-	-	-	A
Furosemide or Bumetanide	Optional [100 mg] Optional [4 mg]	-	-	A	A
Glucagon	2 mg	-	A	A	A
Glucose, oral	Optional [30 gm]	A	A	A	A
Hemostatic Agents	Optional	A	A	A	A
Hydrocortisone Sodium Succinate	Optional	-	*	*	*
<u>Hydroxyethyl Starch with Lactated Ringers</u>	<u>Optional</u>				
Immunizing Agent	Optional	-	-	A	A
Ipratropium Bromide 0.02% SVN or MDI	5 mL	-	-	A	A
Ketamine	Optional [200 mg]	-	-	-	A
Lactated Ringers	1 L bag (2)	A	A	A	A
<u>Lidocaine (IO insertion)</u>	<u>Optional</u>				
Magnesium Sulfate	5 g	-	-	-	A
Methylprednisolone Sodium Succinate	Optional [250 mg]	-	-	A	A
Morphine Sulfate or Fentanyl	20 mg 200 mcg	-	A	A	A
Nalmefene HCl	Optional [4 mg]	-	A	A	A
Naloxone HCl	10 mg	-	A	A	A
Naloxone HCl	Optional [prefilled atomizers or auto-injectors] 2 doses	A	A	A	A
Nitroglycerin Sublingual Spray or Nitroglycerin Tablets	1 bottle 1 bottle	* *	A A	A A	A A
Normal Saline	1 L bag (2) Optional [250 mL bag (1)] Optional [50 mL bag (2)]	A	A	A	A
Ondansetron HCl	Optional [4 mg]	-	-	A	A
Oxygen	13 cubic feet	A	A	A	A
Oxytocin	Optional [10 units]	-	-	A	A
Phenylephrine Nasal Spray 0.5%	Optional [1 bottle]	-	-	A	A
Pralidoxime Chloride Auto-Injector	None	A	A	A	A
Proparacaine Ophthalmic	Optional [1 bottle]	-	-	A	A
Rocuronium	Optional [100 mg]	-	-	-	A
Sodium Bicarbonate 8.4%	Optional [100 mEq]	-	-	A	A
Succinylcholine	Optional [400 mg]	-	-	-	A
Thiamine HCl	100 mg	-	-	A	A
Tuberculin PPD	Optional [5 mL]	-	-	A	A
<u>Tranexamic Acid (TXA)</u>	<u>Optional</u>				
Vasopressin	Optional [40 units]	-	-	-	A

Attachment Vc

GENERIC NAME: Hydroxyethyl starch in Lactated Ringer's

BRAND NAME: HEXTEND

CLASS: plasma volume expander

Mechanism of Action:

Agent is a plasma expander via its support of intravascular oncotic pressure.

Indications for Field Use:

Traumatic injury with massive blood loss unresponsive to crystalloid resuscitation.

Contraindications:

- Known hypersensitivity to hydroxyl ethyl starch (generic name) or Hextend, Hetastarch or Hespan (trade names).
- Known or suspected septic patient. (Black Box warning for hydroxyl ethyl starch with normal saline (Hetastarch, Hespan). Known lactic acidosis.
- Known severe liver disease.
- Known pre-existing coagulation or bleeding disorders.
- Known severe renal disease.

Adverse Reactions:

Rare: Hypersensitivity/anaphylactic reactions. Headache. Possible exacerbation of pre-existing CHF. Lactic acidosis. Coagulopathy.

NOTES ON ADMINISTRATION

Incompatibilities/Drug Interactions:

-As it contains calcium it cannot be infused in the same line as blood products.

Adult Dosage:

500-1000cc bolus, titrated for effect (e.g. SBP > 90, improvement in mentation, skin color, capillary refill)

Pediatric Dosage:

Not approved at this time.

Attachment Vc

Routes of Administration:

IV/IO

Onset of Action:

Immediately upon entering vasculature, dependent on degree of vascular integrity.

Peak Effects:

Dependent on vascular integrity.

Duration of Action:

Can be detected in plasma for 24 to 36 hours, dependent on renal and hepatic status.

Dosage Forms/Packaging:

Arizona Drug Box Standard Supply:

PARAMEDIC: 1 liter

INTERMEDIATE: Not allowed to carry.

Special Notes:

- + Hydroxy ethyl starch in Lactated Ringers is a pale yellow solution. Do not use if brown or a precipitate is detected. Store at room temperature but "brief" exposures to 40 degrees Celsius do not damage the product.
- ***Special Training Requirement***

GENERIC NAME: Tranexamic Acid

BRAND NAME: Cyklokapron, Lysteda (oral formulation)

CLASS: Antifibrinolytic agent. Antiplasminogen activation agent.

"Miscellaneous coagulation modifier."

Mechanism of Action:

Tranexamic acid is a competitive inhibitor of plasminogen activation and at high concentration a non-competitive inhibitor of plasmin. Both actions lead to inhibition of thrombolysis and thereby prevention of dissolution of already-formed fibrin clot.

Indications for Field Use:

Treatment of recent (<3 hours post injury) adult trauma patient with uncontrollable hemorrhage and with sustained tachycardia (>120/min) and hypotension (SBP<90) despite crystalloid fluid resuscitation.

Contraindications:

Tranexamic Acid injection is contraindicated:

1. In patients with acquired defective color vision, since this prohibits measuring one endpoint that should be followed as a measure of toxicity.
2. In patients with suspected subarachnoid hemorrhage. Anecdotal experience indicates that cerebral edema and cerebral infarction may be caused by CYKLOKAPRON in such patients.
3. In patients with known active intravascular clotting (PE or DVT).
4. In patients with hypersensitivity to tranexamic acid or any of the ingredients.
5. Patients known to be taking medroxyprogesterone (Depo-Provera).

Adverse Reactions:

Gastrointestinal disturbances (nausea, vomiting, and diarrhea) may occur. Allergic dermatitis, giddiness, and hypotension have been reported occasionally. Hypotension has been observed when intravenous injection is too rapid.

NOTES ON ADMINISTRATION

Incompatibilities/Drug Interactions:

-Not to be administered in same IV line as blood products, antibiotics or vasopressors.

-Theoretically patients receiving hormone therapies or on oral contraceptives could be predisposed to thrombotic events. When given for traumatic

Attachment V.e.

hemorrhage, these interactions would not be clinically significant. Likewise, interference with anti-platelet or anticoagulant medications could be expected.

Adult Dosage:

Bolus: Mix 1 g in 100cc NS and give over 10 minutes.

Drip: Mix 1 g in 1 liter NS and give at 120cc/hour.

Pediatric Dosage:

Not well studied, so not approved for Pediatric use at this time

Routes of Administration:

IV/IO

Onset of Action:

5-15 minutes

Peak Effects:

Thought to be between 15 minutes and 3 hours

Duration of Action:

An antifibrinolytic concentration of tranexamic acid remains in different tissues for about 17 hours, and in the serum, up to seven or eight hours.

Dosage Forms/Packaging:

10 ml ampules or vials, 100 mg/ml (1g per ampule or vial)

Arizona Drug Box Standard Supply:

PARAMEDIC: 2g

INTERMEDIATE: not allowed

Special Notes:

+ Store at room temperature. Excretion is entirely renal, but there is no effect on magnitude of initial bolus dose. Do not, however, proceed with maintenance infusion in a patient with known renal insufficiency.

Special Training Requirement